» Articles » PMID: 19861503

Glucose Promotes the Production of Interleukine-1beta and Cyclooxygenase-2 in Mesangial Cells Via Enhanced (Pro)renin Receptor Expression

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2009 Oct 29
PMID 19861503
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

(Pro)renin receptor (PRR) is present in renal glomeruli, and its expression is up-regulated in diabetes. Similarly, renal inflammation is increased in the presence of hyperglycemia. The linkage between PRR and renal inflammation is not well established. We hypothesized that glucose-induced up-regulation of PRR leads to increased production of the proinflammatory factors IL-1beta and cyclooxygenase-2 (COX-2). Studies were conducted in rat mesangial cells (RMCs) exposed to 30 mm D-glucose for 2 wk followed by PRR small interfering RNA knockdown, IL-1 receptor blockade with IL-1 receptor antagonist or angiotensin II type 1 receptor blockade with valsartan. The results showed that D-glucose treatment up-regulates prorenin, renin, angiotensin II, PRR, IL-1beta, and COX-2 mRNA and protein expression and increases phosphorylation of ERK1/2, c-Jun N-terminal kinase, c-Jun, and nuclear factor-kappaB (NF-kappaB) p65 (serine 276,468 and 536), respectively. PRR small interfering RNA attenuated PRR, IL-1beta, and COX-2 mRNA and protein expressions and significantly decreased angiotensin II production and phosphorylation of ERK1/2 and NF-kappaB p65 associated with high glucose exposure. Similarly, IL-1 receptor antagonist significantly reduced COX-2 mRNA and protein expression induced by high glucose. COX-2 inhibition reduced high-glucose-induced PRR expression. We conclude that glucose induces the up-regulation of PRR and its ligands prorenin and renin, leading to increased IL-1beta and COX-2 production via the angiotensin II-dependent pathway. It is also possible that PRR could enhance the production of these inflammatory cytokines through direct stimulation of ERK1/2-NF-kappaB signaling cascade.

Citing Articles

GLUT1 and prorenin receptor mediate differential regulation of TGF-β and CTGF in renal inner medullary collecting duct cells during high glucose conditions.

Larenas P, Cardenas P, Aguirre-Delgadillo M, Moris C, Casarini D, Vallotton Z Biol Res. 2024; 57(1):81.

PMID: 39506854 PMC: 11542404. DOI: 10.1186/s40659-024-00560-8.


Renal Expression and Localization of the Receptor for (Pro)renin and Its Ligands in Rodent Models of Diabetes, Metabolic Syndrome, and Age-Dependent Focal and Segmental Glomerulosclerosis.

Iacobini C, Vitale M, Sentinelli F, Haxhi J, Pugliese G, Menini S Int J Mol Sci. 2024; 25(4).

PMID: 38396894 PMC: 10888662. DOI: 10.3390/ijms25042217.


Utilizing molecular docking and cell validation to explore the potential mechanisms of lupenone attenuating the inflammatory response via NF-κB pathway.

Wang X, Liu M, Li X, Zhang M, Xu F, Liu H Sci Rep. 2024; 14(1):625.

PMID: 38182871 PMC: 10770388. DOI: 10.1038/s41598-024-51150-3.


Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects.

Ouyang X, Xu C J Cancer Res Clin Oncol. 2022; 149(6):2595-2605.

PMID: 36153775 DOI: 10.1007/s00432-022-04373-8.


Hormone-Dependent Regulation of Renin and Effects on Prorenin Receptor Signaling in the Collecting Duct.

Lara L, Gonzalez A, Hennrikus M, Prieto M Curr Hypertens Rev. 2022; 18(2):91-100.

PMID: 35170417 PMC: 10132771. DOI: 10.2174/1573402118666220216105357.


References
1.
Keyse S . Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008; 27(2):253-61. DOI: 10.1007/s10555-008-9123-1. View

2.
Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer J . Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 1996; 50(6):1897-903. DOI: 10.1038/ki.1996.511. View

3.
Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi A, Uddin M . Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol. 2007; 18(6):1789-95. DOI: 10.1681/ASN.2006091062. View

4.
Doller A, Akool E, Muller R, Gutwein P, Kurowski C, Pfeilschifter J . Molecular mechanisms of cyclosporin A inhibition of the cytokine-induced matrix metalloproteinase-9 in glomerular mesangial cells. J Am Soc Nephrol. 2007; 18(2):581-92. DOI: 10.1681/ASN.2006060568. View

5.
Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M . Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther. 2004; 311(3):989-95. DOI: 10.1124/jpet.104.072066. View